Company intelligence

BCAX

Bicara Therapeutics Inc. Common Stock · NASDAQ · Healthcare

Price$24.55-0.12% · −$0.03

Market cap1.61BEquity value

P / E-7.9Trailing ratio

Volume191.43KLatest session

Market data

BCAX price chart

TradingView

Related signals

1 min delayed

Browse public BCAX signals with their source context and measured market impact. Open any signal for its permanent analysis page.

BCAXAug 12, 2026+0.55% since signal

Bicara Q2 loss narrows; near-term upside hinges on guidance

BCAX reported a narrower-than-expected Q2 loss, but the snippet provides no revenue or forward guidance. The near-term catalysts depend on management commentary about cash burn, operating runway, and any pipeline updates or trial progress. Investors should watch for updated guidance and new data in upcoming releases.

View signal analysis

BCAXSep 14, 2024+8.54% since signal

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

Bicara Therapeutics raised $315 million at a $1 billion market cap. Company aims to improve cancer treatment targeting EGFR and TGF-ß. Expected Phase 2/3 trial data by late 2024 or early 2025. IPO activity includes seven filings, with strong performance in recent debuts. Market retains optimism as IPO index and S&P 500 show positive trends.

View signal analysis

Research